Z-Drugs and Zopiclone Dependency: The UKs Over-Prescribed Sleeping Pill Problem

Z-drugs like zopiclone and zolpidem were marketed as a safer alternative to benzodiazepines, but they act on the same GABA-A receptor mechanism and carry comparable dependence risk. UK prescribing data shows millions of people taking these “short-term” sleeping pills continuously for years, often without ever misusing the prescription. This article explains why dependence develops even at the prescribed dose, how to recognise the warning signs, and what safe, medically supervised withdrawal actually involves.

It usually starts with something ordinary. A stretch of bad weeks — a bereavement, a divorce, a new baby, a stressful project at work — and a GP appointment that ends with a short course of zopiclone or zolpidem to get through it. The prescription runs out, the “bad weeks” are technically over, but sleep never quite returns to normal. A repeat prescription follows. Then another. Years later, the person taking it can no longer remember what it feels like to fall asleep without the little white or blue pill on the bedside table. The dose that used to work doesn’t work as well any more. Mornings arrive with a fog that coffee doesn’t fully clear. And somewhere along the way, what began as a short-term medical fix quietly became something else.

For families, this is often the hardest kind of dependency to name. A partner or a parent might notice the signs — a changed temper, more secrecy around how many pills are left in the packet, a pattern of ringing the surgery for an early repeat — but struggle to call it what it is. Surely a sleeping tablet from a GP, taken exactly as prescribed, can’t be “a real addiction.” That instinct is understandable, and it is also exactly why so many people go untreated for years.

Zopiclone and zolpidem, collectively known as Z-drugs, were introduced and marketed as the safer, gentler alternative to benzodiazepines — a modern answer to an old problem. UK prescribing data over the past two decades tells a very different story. This article looks at what Z-drugs actually are, how common long-term use has become across the NHS, why dependence can develop even at a “normal” prescribed dose, what the warning signs look like from both the inside and the outside, and what safe, medically supervised withdrawal and treatment actually involve.

What Are Z-Drugs, and Why Were They Prescribed as a “Safer” Alternative to Benzodiazepines?

Z-drugs is the informal name given to a small group of non-benzodiazepine hypnotics developed from the late 1980s onwards: zopiclone, zolpidem, and zaleplon (zaleplon is no longer marketed in the UK). Despite the different chemical class and the different-sounding name, all three act on the same GABA-A receptor complex in the brain as benzodiazepines — the same mechanism that produces sedation, muscle relaxation, and, over time, tolerance and dependence. When Z-drugs launched, they were positioned to prescribers and patients alike as a new generation of sleeping tablet: effective for insomnia, but without the baggage of dependency that had made benzodiazepines like diazepam and temazepam controversial since the 1980s.

The evidence never quite supported that reputation. The National Institute for Health and Care Excellence addressed this directly in Technology Appraisal TA77, “Zaleplon, zolpidem and zopiclone for the short-term management of insomnia,” first published in 2004 and last reviewed in 2010. NICE’s appraisal found no compelling evidence to distinguish zolpidem, zopiclone, or the short-acting benzodiazepines from one another on either efficacy or safety grounds. Its recommendation was correspondingly pragmatic: prescribe whichever of these drugs is cheapest, and only for short courses, strictly within their licensed indications for the short-term management of insomnia.

In other words, the “safer alternative” framing that shaped a generation of prescribing decisions was, by NICE’s own analysis, more of a marketing and cost narrative than a clinical one. The pharmacology — and with it, the risk of dependence — is fundamentally the same as it is for benzodiazepines. NICE’s guidance was clear that these medicines are meant for two to four weeks at most. What actually happens in general practice across the UK looks very different, and that gap is where dependency quietly takes root.

How Common Is Long-Term Zopiclone and Zolpidem Use in the UK?

The scale of long-term Z-drug and benzodiazepine prescribing in England is not a minor statistical footnote — it is one of the more striking findings in recent NHS prescribing research. A 2017 study by Davies, Rae and Montagu, published in the British Journal of General Practice under the title “Long-term benzodiazepine and Z-drugs use in England: a survey of general practice,” found that approximately 16 million prescriptions for benzodiazepines and Z-drugs were issued in England in 2015 alone. That volume had remained broadly steady since 2011, despite clinical guidance consistently limiting these medicines to short courses.

Public Health England went further in its September 2019 evidence review, “Dependence and withdrawal associated with some prescribed medicines.” Looking across five classes of medicine with known dependence or withdrawal potential — benzodiazepines, Z-drugs, gabapentinoids, opioids, and antidepressants — PHE found that 11.5 million adults in England, representing 26% of the adult population, had been prescribed at least one of these medicines in 2017/18. Perhaps the most telling figure in the entire review: roughly half of patients in each of the five classes were continuous users for twelve months or longer. For a category of drug that clinical guidance says should be used for two to four weeks, having half of all patients still taking it a year later is not an edge case. It is close to the norm.

More recent data from the Care Quality Commission‘s 2023 annual update on national trends in controlled drug prescribing, drawn from NHS Business Services Authority ePACT2 data, found that diazepam and zopiclone together accounted for 68% of all Schedule 4 controlled drug prescribing in England that year. Between them, one benzodiazepine and one Z-drug make up more than two-thirds of an entire regulatory category of prescribing.

Taken together, these figures point to something worth naming plainly: this is not a fringe issue affecting a handful of unlucky patients. It is one of the most quietly normalised forms of prescription dependence operating inside the NHS system today, sustained not by illicit use but by repeat prescriptions issued in good faith, appointment after appointment, year after year.

Why Do Z-Drugs Cause Dependence Even When Taken “As Prescribed”?

One of the most misunderstood aspects of Z-drug dependency is that it does not require misuse in any conventional sense. Someone can take exactly the dose their GP prescribed, exactly as often as instructed, and still develop a genuine physical dependence. The mechanism is tolerance: with repeated stimulation, GABA-A receptors in the brain become progressively less sensitive to the drug. The dose that once reliably produced sleep stops working as well. From here, dose creep often begins — not through any deliberate decision to misuse the medication, but through the ordinary, human logic of taking a little more to get the effect that used to come from less, frequently without the prescriber ever being told.

The scale of this problem across Europe was documented by Schifano, Chiappini, Corkery and Guirguis in their 2019 paper “An Insight into Z-Drug Abuse and Dependence,” published in the International Journal of Neuropsychopharmacology. Drawing on the European Medicines Agency’s adverse event database, the researchers identified 33,240 cases of misuse, abuse, dependence, or withdrawal linked to Z-drugs — 23,420 involving zolpidem, 9,283 involving zopiclone, and 537 involving zaleplon. Notably, zopiclone was disproportionately associated with overdose-related adverse reactions within that dataset.

There is also a counterintuitive twist to how dependence presents at higher or more chronic doses. As tolerance develops and the drug’s receptor specificity becomes less precise, some users experience effects that are the opposite of what the medication was ever meant to produce: stimulant-like arousal, disinhibition, or a kind of euphoria, rather than sedation. A person taking a sleeping pill can, paradoxically, end up more wired, not less. A 2025 case report in Frontiers in Psychiatry, “Dependence on zopiclone: a case report,” illustrates exactly this trajectory — a patient whose zopiclone dependence escalated gradually over years of continuous use that was, on paper, entirely “prescribed.”

This is precisely why Holina Rehab treats Z-drug dependency as a genuine addiction requiring proper medical detox, not as a bad habit that can simply be willed away with more discipline or a stronger resolve to “just stop.” The neurochemistry does not distinguish between a prescription taken faithfully for years and any other pathway into dependence — and neither should the treatment response.

What Are the Warning Signs of Zopiclone or Zolpidem Addiction?

Because Z-drug dependency develops gradually and inside a legitimate medical relationship, the warning signs are easy to miss or rationalise — both for the person taking the medication and for the people around them.

From the inside, the pattern often looks like this: taking the pill earlier in the evening than intended, or reaching for a second dose in the middle of the night when the first one wears off too soon. Ringing the surgery for an early repeat prescription, or in more advanced cases, sourcing extra supply from more than one GP or from online pharmacies. Feeling impaired the next day despite believing you are fully awake — daytime sedation, slower reaction times, memory lapses, and impaired coordination that the person themselves often doesn’t connect back to the previous night’s dose.

This next-day impairment risk is not a fringe concern; it has drawn attention from regulators outside the UK specifically. Health Canada issued a Summary Safety Review of Imovane (zopiclone) addressing next-day impairment, and the US Food and Drug Administration issued a 2019 Drug Safety Communication on eszopiclone (marketed as Lunesta), after both regulators found that same-morning blood levels of these drugs could remain high enough to impair driving-relevant skills even in patients who felt completely alert. Regulators in Canada and the United States have taken direct regulatory action — lowering recommended starting doses — on this exact risk profile, and UK product information for zopiclone carries comparable warnings against next-day driving.

Then there is rebound: insomnia, anxiety, or irritability that flares up within 24 to 48 hours of missing a dose. This is one of the cruellest features of Z-drug dependency, because it is so easily misread. The person experiencing it often interprets the rebound symptoms as proof that they genuinely cannot sleep without the medication — when in fact what they are feeling is withdrawal, not an underlying insomnia that has returned unchanged.

For families and partners watching from the outside, the signs tend to look different: secrecy about how many pills are left or how often more have been requested, drowsiness at odd or unexpected hours of the day, mood swings that don’t track with anything else going on, and a tendency to minimise or deflect when the subject is raised directly.

What Does Safe Withdrawal From Z-Drugs Actually Look Like?

Stopping Z-drugs abruptly after long-term or high-dose use carries real and, in some cases, serious risk. Because zopiclone and zolpidem act on the same GABA-A mechanism as benzodiazepines, cold-stopping can produce a strikingly similar withdrawal picture: rebound insomnia, heightened anxiety, and — in cases involving high doses over long periods — a genuine risk of seizure.

UK prescribing guidance reflects this. Regional NHS formulary guidance, including deprescribing guidance issued by NHS Grampian and the Nottinghamshire Area Prescribing Committee for benzodiazepines and Z-hypnotics, recommends that discontinuation always be planned and gradual, typically carried out over a minimum of four to six weeks, with longer timelines for people who have been on the medication for years rather than months. This is the same principle Holina applies in its companion piece on benzodiazepine withdrawal, Benzodiazepine Taper — the timing and rate of dose reduction matter every bit as much as the eventual destination.

This is also why home or GP-managed tapering, while it works for some, fails for a meaningful number of people attempting to come off Z-drugs on their own. Outside a clinical setting, there is typically no 24-hour monitoring to catch a deteriorating withdrawal course early, no structured way to manage the rebound anxiety that almost inevitably surfaces partway through a taper, and — critically — no behavioural health support addressing the underlying insomnia that led to the prescription in the first place. Reducing the dose without addressing what’s underneath it often means the taper stalls, or the person returns to the medication the moment sleep becomes difficult again.

How Holina Rehab Treats Zopiclone and Z-Drug Dependency

Most clients who come to Holina for Z-drug dependency did not set out to become dependent on anything. They started zopiclone or zolpidem for a legitimate, often genuinely short-term insomnia issue, and the prescription simply never stopped. Holina treats this as exactly what it is — a genuine prescription drug addiction requiring proper medical care — never as a moral failing or a matter of personal willpower.

Treatment begins with a medically supervised taper and detox: a gradual, carefully monitored reduction in dose, applying the same clinical caution used in Holina’s benzodiazepine protocol, with rebound insomnia and rebound anxiety managed under 24-hour medical supervision rather than left for the client to weather alone.

Because chronic insomnia and anxiety so often travel together with Z-drug dependency, Holina approaches them through its Dual Treatment programme, not dual diagnosis — the co-occurring insomnia and anxiety are treated as part of one connected clinical picture rather than as two separate problems competing for attention.

Alongside the medical taper, clients engage in Holina’s Sleep, Circadian Rhythm & Recovery work, which is built specifically around rebuilding natural sleep architecture without relying on pharmacological support to get there. NARM and somatic therapy address the nervous-system dysregulation that frequently sits underneath chronic insomnia, long after the original life stressor that triggered it has passed. Hyperbaric oxygen therapy (HBOT) supports neurological recovery during and after the detox process. Because rebound insomnia risk can persist well beyond discharge, Holina’s Thrucare programme provides two years of extended aftercare specifically designed to catch and manage that risk over the long term. Mindfulness and Buddhist-influenced practice, together with family therapy, help clients and their families rebuild sleep habits and family dynamics that, in many cases, have been shaped for years around a medicated version of rest.

All of this takes place in Holina’s Thailand-based, private treatment environment, built for an international clientele, under the care of our clinical team. For many clients, part of the value is simply distance — a discreet, medically led setting removed from the GP relationship and surgery where the original prescription began, and from the routines that have kept the dependency going.

What Families Can Do Now

If you recognise these patterns in someone you love, resist the urge to confront the prescription directly or demand they stop immediately. This isn’t caution for its own sake — cold-stopping a high dose taken over a long period genuinely carries rebound and seizure risk, and an abrupt demand to quit can push someone toward doing exactly that on their own.

Start instead with a private, non-confrontational conversation about what you’ve actually noticed: the earlier evening dose, the early repeat requests, the daytime grogginess. Say it without shaming. Most NHS deprescribing guidance assumes a GP-led taper is the starting point, so encouraging a conversation with their doctor about a supervised reduction plan is a reasonable and low-friction first step — but if that has already been tried and hasn’t held, structured medical detox exists for exactly that situation. If you would like to talk it through confidentially, you can speak with our admissions team at any time.

Try to avoid two opposite traps: enabling the pattern by quietly covering for it, and issuing ultimatums that only push the use further underground and further from honest conversation. Where you can, offer to help research options together, rather than presenting a decision that’s already been made for them.

Frequently asked questions

Is zopiclone actually addictive, or is that overstated?

It is genuinely addictive, not overstated. Schifano and colleagues’ 2019 review of EMA adverse event data identified 33,240 cases of Z-drug misuse, abuse, dependence, or withdrawal. NICE’s own Technology Appraisal TA77 recommends these drugs only for short-term use precisely because of this dependence potential.

How long can you safely take zopiclone or zolpidem?

NICE TA77 and UK prescribing guidance both recommend a maximum of two to four weeks. In practice, Public Health England’s 2019 review found that roughly half of all patients across each dependency-risk medicine class, including Z-drugs, remained on continuous treatment for twelve months or more.

Can you become dependent on zopiclone even at the prescribed dose?

Yes. Tolerance and physical dependence can develop without any deliberate dose escalation, simply through repeated use over time. The 2025 Frontiers in Psychiatry case report and the Schifano et al. research both document dependence emerging from continuous, technically “prescribed” use.

What’s the difference between zopiclone and zolpidem addiction risk?

Both act on the same GABA-A receptor mechanism and carry comparable dependence risk. Schifano et al.’s EMA data shows both drugs heavily represented in dependence and withdrawal reports, with zopiclone showing a stronger association with overdose-related adverse reactions specifically.

Is it dangerous to stop taking zopiclone suddenly?

For long-term or high-dose users, yes. Sudden cessation can trigger rebound insomnia, heightened anxiety, and, in more severe cases, seizures. UK regional prescribing guidance recommends a gradual, medically supervised taper over a minimum of four to six weeks rather than stopping abruptly.

Why did my GP prescribe this for years if it’s only meant for short-term use?

This is more common than most patients realise. Public Health England’s 2019 review found that continuous, long-term prescribing occurs across all five medicine classes it studied, including Z-drugs, despite clinical guidance consistently recommending short courses only.

Does Holina Rehab treat prescription sleeping pill addiction, or only illegal drugs?

Holina treats prescription drug dependence, including Z-drug and benzodiazepine addiction, as a core part of its clinical work. Many clients arrive having never used an illegal substance in their life — their dependence began entirely within a legitimate medical relationship.

What happens during Z-drug detox at Holina?

Treatment begins with a medically supervised taper, alongside dual treatment for co-occurring insomnia and anxiety, NARM and somatic therapy for underlying nervous-system dysregulation, HBOT to support neurological recovery, structured sleep and circadian rhythm rebuilding, and family therapy.

Will I ever be able to sleep without medication again?

We won’t promise a guaranteed outcome, because no honest clinical answer can. What Holina offers is a structured approach — rebuilding circadian rhythm and sleep architecture, addressing the nervous-system and behavioural health factors underneath chronic insomnia, and giving that process the time and medical support it needs to work.

Is zopiclone a controlled drug in the UK?

Yes. Zopiclone is a Schedule 4 Part I controlled drug under the Misuse of Drugs Regulations. The Care Quality Commission’s 2023 controlled drugs report found that zopiclone, together with diazepam, accounted for 68% of all Schedule 4 prescribing in England that year.

Clinically reviewed by Dr. Natalie Lindemann — Clinical Director, Holina Global · Last reviewed 18 August 2026.